Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Amai Proteins

Tracked across 2 events · 12 articles · First seen Jun 08, 2026 · Last active Aug 31, 2026

Sentiment
75
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 80
Tech
Impact: Amai Proteins announced the publication of the world's first clinical study on sweet proteins, confirming the safety and metabolic neutrality of its product, Jan Pieterszoon Sweelinck. This milestone strengthens its commercial credibility and accelerates market adoption.
Jun 08, 2026 · 6 articles
2 70
Regulatory
Impact: Amai Proteins is the developer of sweelin and the primary beneficiary of the Israeli approval, which expands its commercial reach and validates its technology. This third regulatory clearance in six months strengthens its market position and growth prospects.
Jul 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Amai Proteins live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.